CLINICAL_TRIALS
trial_result
· 2012-07-26
Clinical Trial Update: Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection [Phase 3]
Summary
Phase 3 trial comparing 48 weeks of clevudine 30 mg to lamivudine 100 mg for chronic hepatitis B. The update reports on efficacy and safety outcomes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bukwang Pharmaceutical | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED